Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0QDWDN)
| ADC Name |
SC-005
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
SC-005
Click to Show/Hide
|
|||||
| Organization |
Stemcentrx (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Antibody Name |
Undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
PBD dimer
|
Payload Info | ||||
| Payload Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Histologically or cytologically confirmed advanced TNBC that is relapsed, refractory, or progressive and not eligible for another standard therapy that would confer clinical benefit to the subject.
|
||||
| Administration Dosage |
SC-005 intravenous (IV) (various doses and dose regimens)
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03316794 | Clinical Status | PHASE1 | ||
| Clinical Description | An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) | ||||
| Primary Endpoint |
Number of Participants with Dose-limiting Toxicities (DLTs) [Time Frame: Minimum 21 days]
|
||||
| Other Endpoint |
QTcF Change from Baseline [Time Frame: Up to approximately 9 weeks]; Area Under the Plasma Concentration-time Curve (AUC); Clinical benefit rate (CBR); Maximum plasma concentration observed (Cmax); Overall Survival (OS); Observed Plasma Concentrations at Trough; Duration of Clinical Benefit (DOCB)
|
||||